Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023

Bill 118 s 1852, also known as the Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023, is a piece of legislation introduced in the US Congress with the aim of addressing issues related to sickle cell disease and other heritable blood disorders.

The bill focuses on four key areas: research, surveillance, prevention, and treatment. In terms of research, the bill calls for increased funding for research into sickle cell disease and other heritable blood disorders. This includes funding for studies on the causes of these diseases, potential treatments, and ways to improve the quality of life for those affected.

In terms of surveillance, the bill calls for the establishment of a national surveillance system to track the prevalence of sickle cell disease and other heritable blood disorders. This system would help to identify trends in the prevalence of these diseases and inform public health efforts to prevent and treat them. In terms of prevention, the bill calls for the development of strategies to prevent sickle cell disease and other heritable blood disorders. This includes promoting genetic counseling and testing, as well as implementing programs to educate the public about the risks and symptoms of these diseases. In terms of treatment, the bill calls for increased access to care for individuals with sickle cell disease and other heritable blood disorders. This includes funding for treatment centers, training for healthcare providers, and support for individuals and families affected by these diseases. Overall, Bill 118 s 1852 aims to improve the lives of individuals affected by sickle cell disease and other heritable blood disorders through increased research, surveillance, prevention, and treatment efforts. It represents a bipartisan effort to address a pressing public health issue and improve outcomes for those affected by these diseases.